[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575303":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":36,"locations":42,"responsibleParty":61,"collaborators":25,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":25,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":25,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Rigshospitalet, Denmark","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fluconazole","EXPERIMENTAL","Intravenous Fluconazole 400 mg single dose in 200 ml saline solution",[13],"Drug: Fluconazole",{"label":15,"type":16,"description":17,"interventionNames":18},"Isotonic saline solution","PLACEBO_COMPARATOR","Intravenous saline solution single dose 200 ml",[19],"Drug: Isotonic saline solution",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","400 mg inravenous Fluconazole, single dose 200 ml",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Intravenous saline solution, single dose 200 ml",[15],[30,34],{"name":31,"affiliation":32,"role":33},"Andreas Røder, MD, PhD, Professor","Urological Research Unit, Department of Urology, Rigshospitalet Blegdamsvej 9, 2100 Copenhagen, Denmark","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":32,"role":33},"Ulla N Joensen, MD, PhD",[37],{"name":38,"role":39,"phone":40,"phoneExt":25,"email":41},"Mie Ynddal, MD","CONTACT","+4535456152","mie.skjoettgaard.ynddal@regionh.dk",[43],{"facility":44,"status":45,"city":46,"state":25,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Department of Urology, Rigshospitalet","RECRUITING","Copenhagen","2100","Denmark","DK",{"type":51,"coordinates":52},"Point",[53,54],12.56553,55.67594,{"lat":54,"lon":53},[57],{"name":58,"role":39,"phone":59,"phoneExt":25,"email":60},"Adreas Røder, MD, PhD, Professor","+4535458789","andreas.roeder@regionh.dk",{"type":33,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Mie Ynddal","MD, PhD-student","100575303","phase-4-introduction-of-mycotic-prophylaxis-at-cystectomy-trial-100575303",false,"NCT06770530","Introduction of Mycotic Prophylaxis At Cystectomy Trial.","IMPACT - the Introduction of Mycotic Prophylaxis At Cystectomy Trial. Perioperative Mycotic Prophylaxis to Reduce Postoperative Complications Following Cystectomy - a Double-blinded, Placebo-controlled, Randomized Trial","IMPACT","Inclusion Criteria:\n\n* Patients 18 years and older\n* Willingness to participate in the study and the ability to understand and sign an informed consent\n* Indication for performing cystectomy\n* The urinary diversion is limited to the ileal conduit\n\nExclusion Criteria:\n\n* Patients with contraindications to Fluconazole. This includes allergies and treatment with non-pausable medication that in combination is contraindicated\n* Patients in active treatment for mycotic infections","ALL","18 Years",{"count":75,"type":76},484,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","This study aims to introduce a perioperative antifungal prophylaxis for patients undergoing cystectomy: surgically removal of the urinary bladder with construction of a urinary diversion. We wish to investigate the effect of antifungal prophylaxis on complications after the operation.",[82],"Cystectomy","2025-01-07",{"date":85,"type":86},"2025-01-13","ACTUAL",{"date":88,"type":86},"2024-06-24",{"date":90,"type":76},"2027-09",{"name":5,"class":6},1]